Living Cell Technologies Limited (LCT.AX)

ASX - ASX Delayed Price. Currency in AUD
0.090.00 (0.00%)
As of 8:04 PM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.09
Bid0.09 x
Ask0.09 x
Day's Range0.09 - 0.09
52wk Range0.04 - 0.11
1y Target EstN/A
Market Cap44.68M
P/E Ratio (ttm)-12.86
Avg Vol (3m)1,321,309
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Business Wire2 months ago

    LCT’s NTCELL® Parkinson’s Trial Results to Be Presented in Berlin

    As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin.

  • Business Wire3 months ago

    Living Cell Technologies' NTCELL® Demonstrates Continued Reversal of Parkinson's Disease

    81 weeks after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease show reversal of the progression of Parkinson’s disease as measured by globally accepted and validated Unified Parkinson’s Disease Rating Scale .

  • Business Wire5 months ago

    LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson’s Disease

    Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics Committee gave its approval on 3 February 2016.